Abstract
The worldwide incidence of malignant melanoma has been steadily increasing, and it has become a major public health problem in many countries. Melanoma has been considered as a prototypical “immunogenic” tumor on the basis of clinical observations showing that primary lesions can spontaneously regress and that immunosuppressed individuals have an increased incidence of melanoma. Thus, various immunological therapies have been intensively conducted for the treatment of melanoma. Interleukin(IL)-27 is a IL-12-related heterodimeric cytokine composed of p28 and EBV-induced gene 3 subunits that are structurally related to the p35 and p40 subunits of IL-12, respectively. Recent studies reveal that IL-27 exhibits not only potent antitumor immune activities via cytotoxic T lymphocytes or natural killer cells but also an antiangiogenic effect. We recently clarified that IL-27 possesses an antiproliferative activity on melanoma cells. This review summarizes antitumor responses induced by IL-27 and novel anti-melanoma activities of IL-27.
Keywords: malignant melanoma, immunological therapies, Antitumor Activities, Interleukin-27, cytokine
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Antitumor Activities of Interleukin-27 on Melanoma
Volume: 10 Issue: 1
Author(s): Hiroshi Nagai, Shuntaro Oniki, Susumu Fujiwara, Mingli Xu, Izuru Mizoguchi, Takayuki Yoshimoto and Chikako Nishigori
Affiliation:
Keywords: malignant melanoma, immunological therapies, Antitumor Activities, Interleukin-27, cytokine
Abstract: The worldwide incidence of malignant melanoma has been steadily increasing, and it has become a major public health problem in many countries. Melanoma has been considered as a prototypical “immunogenic” tumor on the basis of clinical observations showing that primary lesions can spontaneously regress and that immunosuppressed individuals have an increased incidence of melanoma. Thus, various immunological therapies have been intensively conducted for the treatment of melanoma. Interleukin(IL)-27 is a IL-12-related heterodimeric cytokine composed of p28 and EBV-induced gene 3 subunits that are structurally related to the p35 and p40 subunits of IL-12, respectively. Recent studies reveal that IL-27 exhibits not only potent antitumor immune activities via cytotoxic T lymphocytes or natural killer cells but also an antiangiogenic effect. We recently clarified that IL-27 possesses an antiproliferative activity on melanoma cells. This review summarizes antitumor responses induced by IL-27 and novel anti-melanoma activities of IL-27.
Export Options
About this article
Cite this article as:
Nagai Hiroshi, Oniki Shuntaro, Fujiwara Susumu, Xu Mingli, Mizoguchi Izuru, Yoshimoto Takayuki and Nishigori Chikako, Antitumor Activities of Interleukin-27 on Melanoma, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/187153010790827920
DOI https://dx.doi.org/10.2174/187153010790827920 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transfection of CXCR-4 Using Microbubble-Mediated Ultrasound Irradiation and Liposomes Improves the Migratory Ability of Bone Marrow Stromal Cells
Current Gene Therapy Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design The PYRIN Domain in Signal Transduction
Current Protein & Peptide Science Biomedical Applications of Accelerator Mass Spectrometry
Current Analytical Chemistry Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta
Current Molecular Medicine Novel Molecular Targets in Cancer Chemotherapy Waiting for Discovery
Current Medicinal Chemistry - Anti-Cancer Agents Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Disorder in Milk Proteins: Formation, Structure, Function, Isolation and Applications of Casein Phosphopeptides
Current Protein & Peptide Science An Update on NLRP3 Inflammasome Activation by Engineered Nanomaterials
Current Bionanotechnology (Discontinued) Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases
Current Genomics Potential Health Hazards for Cumulative Exposures to Phthalates and Ionizing Radiation in High-Risk Pediatric Population
Mini-Reviews in Medicinal Chemistry Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets Implication of Unfolded Protein Response and Autophagy in the Treatment of BRAF Inhibitor Resistant Melanoma
Anti-Cancer Agents in Medicinal Chemistry Repair and Translesion DNA Polymerases as Anticancer Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Developing the Evidence Base for Cancer Chemoprevention: Use of Meta-Analysis
Current Drug Targets Biosynthesis and Biological Activities of In Vitro Derived Solasodine Glycoalkaloids from <i>Solanum laciniatum</i>
The Natural Products Journal